| |
The Tolvaptan TEMPO 3/4 Clinical Trial is Officially Completed
March 01, 2012 |
Research & Medicine
The last patients have completed the TEMPO 3/4 Study, which was first listed on the FDA Clinical Trials website in January 2007. The data collected from all the study patients will now be reviewed and evaluated by the study directors. When the data review is complete, the pharmaceutical company Otsuka will use this information to decide on the next steps in moving tolvaptan through the drug approval process.
|
Back
|
|
|
|